Literature DB >> 12445661

Human papillomavirus immortalization and transformation functions.

Karl Münger1, Peter M Howley.   

Abstract

The high risk HPVs (such as HPV-16 and HPV-18) that are associated with specific anogenital cancers encode two oncoproteins E6 and E7, which are expressed in the HPV positive cancers. The E7 protein functions in cellular transformation, at least in part, through interactions with pRB and the other pRB related 'pocket proteins'. The major target of the E6 oncoprotein encoded by the genital tract, cancer associated human papillomaviruses is p53. Several lines of evidence suggest that E6 and E7 have additional targets important to the oncogenic potential of the virus. Work from a number of laboratories has focused on determining other activities of HPV relevant to carcinogenesis and identifying additional cellular targets of E6 and E7. This paper will review the state of the field at the time of the 19th International Papillomavirus Workshop in September 2001 with respect to the HPV encoded oncoproteins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12445661     DOI: 10.1016/s0168-1702(02)00190-9

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  232 in total

1.  Aberrant promoter methylation and loss of suppressor of cytokine signalling-1 gene expression in the development of uterine cervical carcinogenesis.

Authors:  R C Sobti; Neha Singh; Showket Hussain; Vanita Suri; Raje Nijhawan; A C Bharti; Mausumi Bharadwaj; B C Das
Journal:  Cell Oncol (Dordr)       Date:  2011-09-21       Impact factor: 6.730

2.  HPV E6 proteins target Ubc9, the SUMO conjugating enzyme.

Authors:  Phillip R Heaton; Adeline F Deyrieux; Xue-Lin Bian; Van G Wilson
Journal:  Virus Res       Date:  2011-04-12       Impact factor: 3.303

3.  Degradation of p53, not telomerase activation, by E6 is required for bypass of crisis and immortalization by human papillomavirus type 16 E6/E7.

Authors:  H R McMurray; D J McCance
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

4.  Human papillomavirus type 8 E6 oncoprotein inhibits transcription of the PDZ protein syntenin-2.

Authors:  Daliborka Lazić; Martin Hufbauer; Paola Zigrino; Stephanie Buchholz; Siamaque Kazem; Mariet C W Feltkamp; Cornelia Mauch; Gertrud Steger; Herbert Pfister; Baki Akgül
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

5.  Interaction of the papillomavirus E8--E2C protein with the cellular CHD6 protein contributes to transcriptional repression.

Authors:  Jasmin Fertey; Ingo Ammermann; Michael Winkler; Reinhard Stöger; Thomas Iftner; Frank Stubenrauch
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

Review 6.  Regulation of apoptosis by the papillomavirus E6 oncogene.

Authors:  Ting-Ting Li; Li-Na Zhao; Zhi-Guo Liu; Ying Han; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

7.  Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells.

Authors:  I Martinez; A S Gardiner; K F Board; F A Monzon; R P Edwards; S A Khan
Journal:  Oncogene       Date:  2007-11-12       Impact factor: 9.867

8.  Transglutaminase 2 inhibits Rb binding of human papillomavirus E7 by incorporating polyamine.

Authors:  Ju-Hong Jeon; Kyung-Ho Choi; Sung-Yup Cho; Chai-Wan Kim; Dong-Myung Shin; Joon-Cheol Kwon; Kye-Yong Song; Sang-Chul Park; In-Gyu Kim
Journal:  EMBO J       Date:  2003-10-01       Impact factor: 11.598

9.  Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques.

Authors:  Jian Yan; Kristina Harris; Amir S Khan; Ruxandra Draghia-Akli; Duane Sewell; David B Weiner
Journal:  Vaccine       Date:  2008-04-14       Impact factor: 3.641

10.  Karyopherin beta3: a new cellular target for the HPV-16 E5 oncoprotein.

Authors:  Ewa Krawczyk; John A Hanover; Richard Schlegel; Frank A Suprynowicz
Journal:  Biochem Biophys Res Commun       Date:  2008-05-01       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.